Hostname: page-component-78c5997874-xbtfd Total loading time: 0 Render date: 2024-11-05T10:49:06.656Z Has data issue: false hasContentIssue false
  • English
  • Français

Improvements in metabolic abnormalities among overweight schizophrenia and bipolar disorder patients

Published online by Cambridge University Press:  15 April 2020

A. Ventriglio ,
A. Gentile ,
R.J. Baldessarini ,
S. Martone ,
G. Vitrani ,
A. La Marca  and
A. Bellomo
A. Ventriglio*
Affiliation:
Section of Psychiatry, University of Foggia, Department of Clinical and Experimental Medicine, Via Gugliemo Marconi 3, 71041 Carapelle (FG), Foggia, Italy
A. Gentile
Affiliation:
Section of Psychiatry, University of Foggia, Department of Clinical and Experimental Medicine, Via Gugliemo Marconi 3, 71041 Carapelle (FG), Foggia, Italy
R.J. Baldessarini
Affiliation:
Department of Psychiatry, Harvard Medical School, International Consortium for Bipolar and Psychotic Disorders Research, McLean Hospital, Belmont, Massachusetts, USA
S. Martone
Affiliation:
Section of Psychiatry, University of Foggia, Department of Clinical and Experimental Medicine, Via Gugliemo Marconi 3, 71041 Carapelle (FG), Foggia, Italy
G. Vitrani
Affiliation:
Section of Psychiatry, University of Foggia, Department of Clinical and Experimental Medicine, Via Gugliemo Marconi 3, 71041 Carapelle (FG), Foggia, Italy
A. La Marca
Affiliation:
Section of Psychiatry, University of Foggia, Department of Clinical and Experimental Medicine, Via Gugliemo Marconi 3, 71041 Carapelle (FG), Foggia, Italy
A. Bellomo
Affiliation:
Section of Psychiatry, University of Foggia, Department of Clinical and Experimental Medicine, Via Gugliemo Marconi 3, 71041 Carapelle (FG), Foggia, Italy
*
*Corresponding author. Tel.: +39 339 646 6525; fax: +39 088 579 9096. E-mail address: [email protected] (A. Ventriglio).
Get access

Abstract

Purpose

As weight-gain and metabolic abnormalities during treatment with psychotropic drugs are of great concern, we evaluated effects of psycho-education and medical monitoring on metabolic changes among severely mentally ill patients.

Materials and methods

During repeated, systematic psycho-education about general health among 66 consecutive patients diagnosed with DSM-IV-TR schizophrenia (n = 33) or type-I bipolar disorder (n = 33), we evaluated (at intake 1, 2, 3, and 6 months) clinical psychiatric status, treatments and doses, recorded physiological parameters, and assessed attitudes about medication.

Results

At intake, patients with schizophrenia vs bipolar disorder were receiving 3–7 times more psychotropic medication, with 14% higher initial body-mass index (BMI: 29.1 vs 25.6 kg/m2), 12 times more obesity, and significantly higher serum lipid concentrations. During 6-months follow-up, among bipolar disorder patients, polytherapy and serum lipid concentrations declined more than among schizophrenia patients (e.g., total cholesterol + triglycerides, by 3.21 vs 1.75%/month). BMI remained stable. Declining lipid levels were associated with older age, bipolar disorder, being unemployed, higher antipsychotic doses, and lower initial BPRS scores (all P ≤ 0.001).

Conclusions

Psychotropic treatments were more complex, and metabolic measures more abnormal among bipolar disorder than schizophrenia patients. Intensive psycho-education, clinical monitoring, and encouragement of weight-control for six months were associated with improvements in metabolic measures (but not to BMI), and more realistic attitudes about medication.

Keywords

Antipsychotic drugsBipolar disorderMetabolic syndromeObesitySchizophreniaWeight-gain
Type
Original article
Information
European Psychiatry , Volume 29 , Issue 7 , September 2014 , pp. 402 - 407
Copyright
Copyright © 2013 Elsevier Masson SAS

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Footnotes

1

Via Paolo Telesforo 33, 71100 Foggia, Italy. Tel.: +39 320 865 2708.

2

Mailman Research Center, McLean Hospital, 115 Mill Street, Belmont, MA, USA 02478-9106. Tel.: +1 617 855 3203; fax: 1 617 855 3479.

3

Via Padre Antonio da Olivadi 12, 71100 Foggia, Italy. Tel.: +39 339 707 4547.

4

Vle G. Di Vittorio 14, 71121 Foggia, Italy. Tel.: +39 349 759 8555.

5

V. le Francia 40, 71122 Foggia, Italy. Tel.: +39 329 427 5189.

6

SPDC presso OORR di Foggia, Vl.le Pinto, 71100 Foggia, Italy. Tel.: +39 080 521 1926.

References

Aekplakorn, W., Chongsuvivatwong, V., Tatsanavivat, P., Suriyawongpaisal, P.Prevalence of metabolic syndrome defined by the international diabetes federation and national cholesterol education program criteria among Thai adults. Asia Pac J Public Health 2011;23(5):792–800.CrossRefGoogle ScholarPubMed
American Diabetes Association. Consensus development conference on antipsychotic drugs, obesity and diabetes. Diabetes Care 2004;27:596–601.CrossRefGoogle Scholar
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed.Washington, DC: American Psychiatric Press; 2000 [text revised (DSM-IV-R)].Google Scholar
Baldessarini, R.J.Chemotherapy in psychiatry. 3rd ed.New York: Springer Press; 2013.CrossRefGoogle Scholar
Baldessarini, R.J., Tarazi, F.I.Drugs and the treatment of psychiatric disorders: antipsychotic and antimanic agents. In: Hardman, J.G., Limbird, L.E., Gilman, A.G. editors. Goodman and Gilman's the pharmacological basis of therapeutics 11th ed.New York: McGraw-Hill; 2005.Google Scholar
Barnett, A.H., Mackin, P., Chaudhry, I., Farooqi, A., Gadsby, R., Heald, A.et al.Minimizing metabolic and cardiovascular risk in schizophrenia. J Psychopharmacol 2007;21(4):2005. p. 357–373.CrossRefGoogle Scholar
Bhuvaneswar, C.G., Baldessarini, R.J., Harsh, V.L., Alpert, J.E.Adverse endocrine and metabolic effects of psychotropic drugs: selective clinical review. CNS Drugs 2009;23(12):1003–1021.CrossRefGoogle ScholarPubMed
Buckley, P.F., Miller, D.D., Singer, B.Clinicians’ recognition of the metabolic adverse effects of antipsychotic medications. Schizophr Res 792–32005 281–288.CrossRefGoogle ScholarPubMed
Cahn, W., Ramlal, D., Bruggeman, R., de Haan, L., Scheepers, F.E., van Soest, M.M.et al.Prevention and treatment of somatic complications arising from the use of antipsychotics. Tijdschr Psychiatr 2008;50(9):579–591.Google ScholarPubMed
Canadian Diabetes, , Association, Clinical Practice Guidelines for the prevention and management of diabetes. Can J Diabetes 2008;32(Suppl 1):S1–S20.Google Scholar
Centorrino, F., Masters, G.A., Talamo, A., Baldessarini, R.J., Öngür, D.Metabolic syndrome in psychiatrically hospitalized patients treated with antipsychotics and other psychotropics. Hum Psychopharmacol 2012;27(5):521–526.CrossRefGoogle ScholarPubMed
Centorrino, F., Sani, G., Fogarty, K.V., Salvatore, P., Talamo, A., Cincotta, S.L.et al.Combinations of mood-stabilizers with antipsychotics as treatment strategies in hospitalized psychiatric patients. Clin Neuropsychiatry J Treat Eval 2006;3(1):322–326.Google Scholar
Centorrino, F., Wurtman, J.J., Duca, K.A., Fellman, V.H., Fogarty, K.V., Berry, J.M.et al.Weight loss in overweight patients maintained on atypical antipsychotic agents. Int J Obes (Lond) 2006;30(6):1011–1016.CrossRefGoogle ScholarPubMed
Citrome, L., Vreeland, B.Schizophrenia, obesity, and antipsychotic medications: what can we do?. Postgrad Med 2008;120(2):18–33.CrossRefGoogle Scholar
Citrome, L., Yeomans, D.Do guidelines for severe mental illness promote physical health and well-being?. J Psychopharmacol 2005;19(6):102–109.CrossRefGoogle ScholarPubMed
Cohn, T.A., Sernyak, M.J.Metabolic monitoring for patients treated with antipsychotic medications. Can J Psychiatry 2006;51(8):492–501.CrossRefGoogle ScholarPubMed
De Hert, M., Dekker, J.M., Wood, D., Kahl, K.G., Holt, R.I.G., Möller, H.-J.Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA) with the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry 2009;24(6):412–424.CrossRefGoogle Scholar
De Hert, M., van Eyck, D., De Nayer, A.Metabolic abnormalities associated with second generation antipsychotics: fact or fiction? Development of guidelines for screening and monitoring. Int Clin Psychopharmacol 2006;21(Suppl 2):S1–S5.CrossRefGoogle ScholarPubMed
De Nayer, A., De Hert, M., Scheen, A., Van Gaal, L., Peuskens, J.Belgian consensus on metabolic problems associated with atypical antipsychotics. Encephale 2007;33(2):197–202.Google ScholarPubMed
Dingemans, P.M., Linszen, D.H., Lenior, M.E., Smeets, R.M.Component structure of the expanded Brief Psychiatric Rating Scale (BPRS- E). Psychopharmacology 1995;122(3):263–267.CrossRefGoogle Scholar
Falissard, B., Mauri, M., Shaw, K., Wetterling, T., Doble, A., Giudicelli, A.et al.The METEOR study: frequency of metabolic disorders in patients with schizophrenia. Focus on first and second generation and level of risk of antipsychotic drugs. Int Clin Psychopharmacol 2011;26(6):291–302.CrossRefGoogle ScholarPubMed
Gardner, D.M., Murphy, A.L., O’Donnell, H., Centorrino, F., Baldessarini, R.J.Equivalent doses of antipsychotic agents: findings from an international Delphi survey. Am J Psychiatry 2010;167(6):686–693.CrossRefGoogle Scholar
Gentile, S.Lxjng-term treatment with atypical antipsychotics and the risk of weight gain: a literature analysis. Drug Saf 2006;29(4):303–319.CrossRefGoogle ScholarPubMed
Grover, S., Malhotra, N., Chakrabarti, S., Kulhara, P.Metabolic syndrome in bipolar disorders. Indian J Psychol Med 2012;34(2):110–118.CrossRefGoogle ScholarPubMed
Haupt, D.W., Rosenblatt, L.C., Kim, E., Baker, R.A., Whitehead, R., Newcomer, J.W.Prevalence and predictors of lipid and glucose monitoring in commercially insured patients treated with second-generation antipsychotic agents. Am J Psychiatry 2009;166(3):345–353.CrossRefGoogle ScholarPubMed
Hogan, T.P., Awad, A.G., Eastwood, R.A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity. Psychol Med 1983;13(1):177–183.CrossRefGoogle ScholarPubMed
Kay, S.R., Fiszbein, A., Opler, L.A.The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987;13(2):261–276.CrossRefGoogle Scholar
Kozlov, A.I., Vershubskaia, G.G., Sanina, E.D., Ateeva IuA, , Potolitsina, N.N., Kaneva, A.M.et al.Blood serum concentration of lipids and lipoproteins and body composition]. Fiziol Cheloveka 2012;38(3):116–123.Google Scholar
Laundon, W., Muzyk, A.J., Gagliardi, J.P., Christopher, E.J., Rothrock-Christian, T., Jiang, W.Prevalence of baseline lipid monitoring in patients prescribed second-generation antipsychotics during their index hospitalization: retrospective cohort study. Gen Hosp Psychiatry 2012;34(4):380–384.CrossRefGoogle ScholarPubMed
Levy, B., Manove, E.Functional outcome in bipolar disorder: the big picture. Depress Res Treat 2012;2012:949248. http://dx.doi.org/10.1155/2012/949248.Google ScholarPubMed
Littrell, K.H., Hilligoss, N.M., Kirshner, C.D., Petty, R.G., Johnson, C.G.The effects of an educational intervention on antipsychotic-induced weight gain. J Nurs Scholarsh 2003;35(3):237–241.CrossRefGoogle ScholarPubMed
Mackin, P., Bishop, D., Watkinson, H.Prospective study of monitoring practices for metabolic disease in antipsychotic-treated community psychiatric patients. BMC Psychiatry 2007;25(1):7–28.Google Scholar
Marder, S.R., Essock, S.M., Miller, A.L., Buchanan, R.W., Casey, D.E., Davis, J.M.et al.Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004;161(8):1334–1349.CrossRefGoogle ScholarPubMed
Newcomer, J.W.Second-generation (atypical) antipsychotics and metabolic effects: comprehensive literature review. CNS Drugs 19Suppl 12005 1–93.CrossRefGoogle ScholarPubMed
Newcomer, J.W., Nasrallah, H.A., Loebel, A.D.Atypical antipsychotic therapy and metabolic issues: national survey. J Clin Psychopharmacol 245 Suppl 12004 S1–S6.CrossRefGoogle ScholarPubMed
Prasko, J., Vrbova, K., Latalova, K., Mainerova, B.Psychoeducation for psychotic patients. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2011;155(4):385–395.CrossRefGoogle ScholarPubMed
Sáiz Ruiz, J., Bobes García, J., Vallejo Ruiloba, J., Giner Ubago, J., García- Portilla González, M.P.Consensus on physical health of patients with schizophrenia from the Spanish Societies of Psychiatry and Biological Psychiatry. Actas Esp Psiquiatr 2008;36(5):251–264.Google ScholarPubMed
Sheehan, D.V., Lecrubier, Y., Sheehan, K.H., Amorim, P., Janavs, J., Weiller, E.et al.Mini-international neuropsychiatric interview (MINI): development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59(Suppl. 20(1)):22–33 [quiz 34–57].Google ScholarPubMed
Vancampfort, D., Vansteelandt, K., Correll, C.U., Mitchell, A.J., De Herdt, A., Sienaert, P.et al.Metabolic syndrome and metabolic abnormalities in bipolar disorder: a meta-analysis of prevalence rates and moderators. Am J Psychiatry 2013;170:265–274.CrossRefGoogle ScholarPubMed
Ventriglio, A., Vincenti, A., Centorrino, F., Talamo, A., Fitzmaurice, G., Baldessarini, R.J.Use of mood stabilizers for hospitalized psychotic and bipolar disorder patients. Int Clin Psychopharmacol 2011;26(2):88–95.CrossRefGoogle ScholarPubMed
Waterreus, A.J., Laugharne, J.D.Screening for the metabolic syndrome in patients receiving antipsychotic treatment: proposed algorithm. Med J Aust 2009;190(4):185–189.CrossRefGoogle ScholarPubMed
Weiden, P.J., Mackell, J.A., McDonnell, D.D.Obesity as a risk factor for antipsychotic noncompliance. Schizophr Res 2004;66(1):51–57.CrossRefGoogle ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.